Welcome to our dedicated page for Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares stock.
Can-Fite BioPharma Ltd. (symbol: CANF) is a clinical-stage biopharmaceutical company headquartered at 10 Bareket Street, פ"ת, Israel. This biotechnology firm specializes in the development of orally bioavailable small molecule therapeutic products aimed at treating a range of conditions including cancer, liver, and inflammatory diseases.
The company leverages its proprietary platform technology, which targets the Gi protein associated A3 adenosine receptor (A3AR) to develop its therapeutic candidates. One of its leading drug candidates, Piclidenoson, is currently undergoing a Phase III clinical trial for psoriasis, indicating its advanced stage in the development pipeline.
Another significant product in Can-Fite's portfolio is Namodenoson. This drug is making strides towards addressing liver-related conditions, with a Phase III trial underway for hepatocellular carcinoma (HCC), the most common form of liver cancer. Additionally, it is in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a serious liver condition with limited treatment options.
Can-Fite BioPharma is committed to improving patient outcomes through innovative therapeutic solutions. The company collaborates with various partners and research institutions to drive its drug development programs forward. Its focus on oral therapeutics provides an added advantage of ease of administration, potentially improving patient compliance and overall treatment efficacy.
This combination of advanced clinical trials, strategic partnerships, and a focused therapeutic approach highlights Can-Fite BioPharma's role as a significant player in the biopharmaceutical industry.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced that CEO Dr. Pnina Fishman will present at the 3rd Annual Dermatology Drug Development Summit on April 6, 2022, showcasing the lead drug candidate Piclidenoson for psoriasis treatment. Enrollment in the Phase III Comfort™ study is complete with 400 patients across 30 sites in Europe, Israel, and Canada, with topline data expected in Q2 2022. The company has received approximately $20 million from licensing agreements, enhancing its market reach in various countries.
Can-Fite BioPharma (NYSE: CANF) announced its financial results for the year ended December 31, 2021, reporting revenues of $0.85 million, up from $0.76 million in 2020. The company had a cash balance of $18.9 million at year-end. Key developments include a significant $42.7 million out-licensing deal with Ewopharma and positive Phase II results for Namodenoson in liver cancer. A Phase III study for liver cancer is set to start in H1 2022, and topline data for psoriasis is expected in Q2 2022.
Can-Fite BioPharma Ltd (NYSE: CANF) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its method to treat advanced liver fibrosis with Namodenoson. This expansion targets various liver conditions including NASH and liver cancer, tapping into a market projected to exceed $20 billion by 2020.
The company is currently enrolling patients for a Phase IIb trial for NASH and plans to begin a Phase III trial for advanced liver cancer. Namodenoson boasts a strong safety profile and significant commercial potential.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced its CEO, Dr. Pnina Fishman, will present research at the CannX Medical Cannabis Conference on March 14-15, 2022, focusing on cannabinoids' role in liver cancer treatment.
Key findings indicate that CBD-rich T3/C15 can inhibit hepatocellular carcinoma growth at low concentrations by activating the A3 adenosine receptor. Can-Fite is exploring collaboration opportunities within the cannabis sector for potential licensing.
The abstract will be published in the Medical Cannabis and Cannabinoids journal.
Can-Fite BioPharma (NYSE American: CANF) announced an unexpected delay in releasing top-line data from its Phase III Comfort™ study of Piclidenoson for treating plaque psoriasis, now expected in Q2 2022. The study involves over 400 patients across Europe, Israel, and Canada. Piclidenoson aims to target key cytokines involved in skin lesions. The psoriasis market is projected to reach $11.3 billion by 2025, with potential milestone payments from out-licensing agreements. The company remains optimistic about the drug's effectiveness with minimal side effects.
Can-Fite BioPharma (NYSE American: CANF) announced the enrollment of the first patient in a Phase IIb study for its drug candidate Namodenoson, targeting non-alcoholic steatohepatitis (NASH). This multicenter, randomized trial aims to assess Namodenoson's efficacy compared to placebo in 140 subjects over 36 weeks. The NASH market is projected to reach $35-$40 billion by 2025, highlighting the growth potential. Previous Phase IIa results indicated promising outcomes related to liver fibrosis and inflammation.
Can-Fite BioPharma (NYSE American: CANF) has out-licensed its psoriasis drug, Piclidenoson, in major markets including Canada, Europe, and Asia. Recent pre-clinical studies show that Piclidenoson effectively destroys pathological skin cells, supporting its potential in treating psoriasis. The ongoing Phase III trial in Europe and Canada aims to demonstrate efficacy via PASI score improvements. The psoriasis market is projected to reach $11.3 billion by 2025, which could enhance Can-Fite's market position with milestone payments and royalties expected upon regulatory approval.
Can-Fite BioPharma (NYSE American: CANF) announced plans to hold virtual investor meetings at the J.P. Morgan Healthcare Conference. The company reported a complete response to Namodenoson for hepatocellular carcinoma (HCC) in its Phase II study. In Q1 2022, patient enrollment for a pivotal Phase III trial for HCC is expected to commence, supported by the FDA and EMA’s approval of the study design. Namodenoson has Orphan Drug Designation in the U.S. and Europe, with Fast Track Status in the U.S.
These developments position Can-Fite favorably in the competitive biopharma landscape.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced key upcoming events expected to enhance shareholder value throughout 2022. The company plans to release topline data from a Phase III psoriasis study in Q1 2022, examining a primary endpoint related to Piclidenoson. Additionally, it will commence enrollment in a Phase IIb NASH study and a Phase III liver cancer study in H1 2022. Can-Fite has raised $10 million recently, complementing $13.3 million reported in Q3 2021, positioning the company well for ongoing clinical trials.
Can-Fite BioPharma Ltd (NYSE American: CANF) announced plans to file new patent applications for Namodenoson, a treatment targeting advanced liver cancer. This follows clinical data where a patient with advanced hepatocellular carcinoma (HCC) exhibited complete tumor clearance after treatment. The company is set to begin patient enrollment for a pivotal Phase III trial in Q1 2022 to support a New Drug Application (NDA). Can-Fite's IP portfolio now includes approximately 200 patents across 16 families, reinforcing its position in treating advanced cancers.
FAQ
What is the current stock price of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?
What is the market cap of Can-Fite BioPharma Ltd. American Depositary Shares, each representing three hundred (300) Ordinary Shares (CANF)?
What does Can-Fite BioPharma Ltd. specialize in?
Where is Can-Fite BioPharma Ltd. located?
What is Piclidenoson?
What is Namodenoson used for?
What stage are the trials for Namodenoson?
What is the A3 adenosine receptor (A3AR)?
How does Can-Fite BioPharma's technology benefit patients?
What is the significance of Can-Fite BioPharma's partnerships?
Is Can-Fite BioPharma listed on any stock exchange?
What is the focus of Can-Fite BioPharma's current projects?
